Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial
Yu‐Pei Chen(Sun Yat-sen University), Jun Ma(Shanghai Institute of Technology), Fang‐Yun Xie(Sun Yat-sen University), Mei Shi(Xijing Hospital), Yanxia Shi(Sun Yat-sen University), San‐Gang Wu(First Affiliated Hospital of Xiamen University), Hong-Fen Wu(Zhengzhou University), Guan‐Qun Zhou(Sun Yat-sen University), Yuan Zhang(Sun Yat-sen University), Huixia Feng(Sun Yat-sen University Cancer Center), Qi Mei(Shantou University), Ying Sun(Key Laboratory of Guangdong Province), Yan Sun(Peking University), Feng Jin(China Medical University), Jing Huang(Sun Yat-sen University), Ling‐Long Tang(Sun Yat-sen University), Kunyu Yang(Macau University of Science and Technology), Cheng Xu(Sun Yat-sen University), Yan‐Ping Mao(Sun Yat-sen University), Qin Lin(Zhongshan Hospital of Xiamen University), Xu Liu(Sun Yat-sen University), Lei Chen(Zhuzhou Central Hospital), Ning Zhang(First People's Hospital of Foshan), Ling Li(Tumor Hospital of Guangxi Medical University), Hui Wang(Yancheng Institute of Technology), Jing Xu(Scuola Internazionale Superiore di Studi Avanzati), Hui Wu(Jishou University), Xiaodong Zhu(Guangxi Medical University), Rui Guo(Sun Yat-sen University), Wei‐Han Hu(Sun Yat-sen University), Guoqing Hu(Tongji Hospital), Qin Zhou(Central South University), Ye Tian(Soochow University), Xicheng Wang(Shanghai East Hospital), Jia‐Wei Lv(Sun Yat-sen University), Zhengzheng Liu(Xiangya Hospital Central South University), Wen‐Fei Li(Sun Yat-sen University), Jian Zang(Shenyang Agricultural University), Rui Sun(Sun Yat-sen University), Xiuling Luo(Guiyang Medical University), Baomin Zheng(Peking University), Liangfang Shen(Central South University), Ying Guo(Sun Yat-sen University), Dan Yue(ShanghaiTech University)
Cited by 234
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
|The Lancet|2008|1.2k
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934